{"disease":{"id":"metastatic-pancreatic-cancer","name":"metastatic pancreatic cancer"},"drugs":{"marketed":[{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic pancreatic cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06106568","title":"An Observational Study to Learn More About the Impact of Gadoxetate Sodium-Enhanced Magnetic Resonance Imaging (EOB-MRI) When Used to Diagnose the Spread of Cancer From the Pancreas to the Liver in Japanese People Under Real-World Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":39624,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT00844649","title":"Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":861,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT01231347","title":"QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"NantCell, Inc.","has_results":true},{"nct_id":"NCT04789980","title":"Good Choice of pALliative Chemotherapy to Patient With Pancreatic Cancer ; GemcitAbine Therapy vs FOLFORINOX therapY","phase":"","overall_status":"COMPLETED","enrollment_count":799,"lead_sponsor_name":"Boryung Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT05380414","title":"Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT07409272","title":"A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":614,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT05714124","title":"Liver Embolization Approaches for Tumor Management","phase":"","overall_status":"RECRUITING","enrollment_count":580,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT04229004","title":"A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":502,"lead_sponsor_name":"Pancreatic Cancer Action Network","has_results":false},{"nct_id":"NCT06361888","title":"A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":502,"lead_sponsor_name":"Hutchmed","has_results":false},{"nct_id":"NCT06861088","title":"The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":480,"lead_sponsor_name":"Quercis Pharma AG","has_results":false},{"nct_id":"NCT03816163","title":"A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":393,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT06967233","title":"Multimodal Managements for Metastatic Pancreatic Cancer.","phase":"","overall_status":"COMPLETED","enrollment_count":360,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT01174121","title":"Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":332,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02555813","title":"Treatment of Pancreatic Cancer With Abraxane","phase":"","overall_status":"COMPLETED","enrollment_count":317,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT02184663","title":"Evaluation of an Adapted Physical Activity Program in Patients With Unresectable Pancreatic Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":313,"lead_sponsor_name":"GERCOR - Multidisciplinary Oncology Cooperative Group","has_results":false},{"nct_id":"NCT05074589","title":"Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":298,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT03693677","title":"First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":288,"lead_sponsor_name":"Federation Francophone de Cancerologie Digestive","has_results":false},{"nct_id":"NCT01839487","title":"PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":279,"lead_sponsor_name":"Halozyme Therapeutics","has_results":true},{"nct_id":"NCT02983500","title":"Patient Reported Outcomes Registry in Patient With Cancer Cachexia","phase":"","overall_status":"COMPLETED","enrollment_count":253,"lead_sponsor_name":"iOMEDICO AG","has_results":false},{"nct_id":"NCT02282722","title":"Improving Informed Consent for Palliative Chemotherapy","phase":"NA","overall_status":"COMPLETED","enrollment_count":216,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":true},{"nct_id":"NCT03620461","title":"Gemcitabine and Nabpaclitaxel in Metastatic Pancreatic Carcinoma.","phase":"","overall_status":"COMPLETED","enrollment_count":210,"lead_sponsor_name":"Galician Research Group on Digestive Tumors","has_results":false},{"nct_id":"NCT03086369","title":"A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":184,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT05065801","title":"Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":162,"lead_sponsor_name":"Institut du Cancer de Montpellier - Val d'Aurelle","has_results":false},{"nct_id":"NCT05042128","title":"The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":158,"lead_sponsor_name":"Australasian Gastro-Intestinal Trials Group","has_results":false},{"nct_id":"NCT03468335","title":"2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":151,"lead_sponsor_name":"AIO-Studien-gGmbH","has_results":false},{"nct_id":"NCT03443492","title":"SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"National Health Research Institutes, Taiwan","has_results":false},{"nct_id":"NCT04101929","title":"Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":126,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03986294","title":"Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":122,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT03929094","title":"Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06662669","title":"YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Shanghai YingLi Pharmaceutical Co. Ltd.","has_results":false},{"nct_id":"NCT04498689","title":"Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":117,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04222413","title":"Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":116,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06621095","title":"Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":104,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT04133155","title":"Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT03261947","title":"A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT01088815","title":"Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":98,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":true},{"nct_id":"NCT03446872","title":"Post Marketing Surveillance Study for ONIVYDE® in South Korea","phase":"","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":false},{"nct_id":"NCT05848154","title":"Application of ctDNA in Evaluation of Neoadjuvant Chemotherapy Efficacy and Exploration of Chemoresistance Mechanisms in Pancreatic Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":92,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT06946901","title":"The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a Phase II Clinical Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT05988814","title":"Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Centre Georges Francois Leclerc","has_results":false},{"nct_id":"NCT03682289","title":"Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":89,"lead_sponsor_name":"Rahul Aggarwal","has_results":false},{"nct_id":"NCT06532331","title":"A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":87,"lead_sponsor_name":"Ono Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT02697058","title":"Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":false},{"nct_id":"NCT06353581","title":"Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOX","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":78,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT03579836","title":"Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"BeyondBio Inc.","has_results":false},{"nct_id":"NCT00398086","title":"Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT01489865","title":"ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Georgetown University","has_results":true},{"nct_id":"NCT05346536","title":"Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC)","phase":"NA","overall_status":"RECRUITING","enrollment_count":63,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT05363007","title":"Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic Adenocarcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT04589234","title":"Saltikva for Metastatic Pancreatic Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Salspera LLC","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}